Dr Reddy’s Debuts US Vimovo Rival At Risk

Lupin Has Authorized Generic As Nuvo Cites Patents To 2022

Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.

Risk
Dr Reddy’s launch of a Vimovo rival is at risk • Source: Shutterstock

Dr Reddy’s has announced the launch of the first US generic version of Vimovo (naproxen/esomeprazole) delayed-release tablets in 375mg/20mg and 500mg/20mg strengths, in bottles of 60 tablets. However, Nuvo Pharmaceuticals – which licenses the product to Horizon Pharma for marketing in the US – has warned that the at-risk launch infringes patents protecting the arthritis treatment until May 2022.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

More from Generics Bulletin